CXCL12 and neoplasm: Additionally, a combination of AMD3100 (a CXCL12/CXCR4 axis inhibitor) and anti-PD-1 therapy significantly reduces tumor growth, suggesting that circ_0020710 contributes to immune evasion through the CXCL12/CXCR4 signaling axis.